BridgeMD
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis.
EU CTIS ID: 2024-519298-21-00
What this study is testing
1.To evaluate the effect of REGN7508 compared to placebo in the prevention of CAT in participants with solid tumors undergoing cancer treatment. 2. To evaluate the effect of REGN7508 compared to placebo on clinically important bleeding events.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol .
- Has a Khorana thromboembolic risk score ≥2 at the time of screening or harbors a somatic documented tumor genetic variant known to be associated with an increased risk of VTE as described in the protocol .
- Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention
- Other Protocol Defined Inclusion Criteria Apply
You likely can't join if
- Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand’s disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy).
- Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma.
- Has a primary brain tumor or brain metastases as described in the protocol
- Has a history of objective evidence of VTE or ATE, including incidental VTE identified by diagnostic imaging requiring anticoagulation.
- Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm if he/she participated in the study.
- Other Protocol Defined Exclusion Criteria Apply.
The study team makes the final eligibility decision.
Where it's taking place
- Taiwan
- United States
- Australia
- United Kingdom
- Georgia
- Canada
- Korea, Democratic People's Republic of
- Japan
- Brazil
- Turkey
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taiwan; United States; Australia; United Kingdom; Georgia; Canada and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.